French software maker Dassault Systemes is in talks to buy drug-trial software maker ArisGlobal from Nordic Capital for about $2 billion, according to the Financial Times.
The potential deal would extend Dassault Systemes’ foray into software used in life sciences and would rank as its second-biggest acquisition after its $5.8 billion takeover of clinical trial software group Medidata Solutions in 2019.
A transaction between the two firms is not a foregone conclusion, and talks could still fall apart, the Financial Times said.
Dassault Systemes, ArisGlobal, and Nordic Capital could not immediately be reached for comment.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
